Has the 1L SoC Truly Changed in Advanced Stage DLBCL?

SOHO Brazil 2024

A. Zelenetz

Current Advances in the Treatment of Aggressive B- and T-Cell Lympho…

Indy Hematology Review

S. Smith

Top 5 Lymphoma Abstracts From ASH

Jennifer Amengual

Treatment Strategies for Hematocrit Control in PV

Insights from 2023 ASH Annual Meeting

A. Zhou

Current Management of DLBCL From Frontline to Relapsed Disease

Dipenkumar Modi

State of the Art and Next Questions: B-Cell Lymphoma

SOHO Highlights: State of the Art and Next Questions

L. Nastoupil

Tafasitamab + Lenalidomide vs. CIT for Transplant-Ineligible R/R DLB…

Patrizia Mondello

Treatment Updates and Management of Non-Hodgkin Lymphomas

Integrity CE

D. Wallace, M. Cortese

Bispecifics for LBCL: Guidance for Management of Toxicities in the C…

UChicago Medicine

J. Crombie

Lymphoma Hot Topics in 2024: Focus on DLBCL and cHL

Yale Cancer Center

T. Sethi

The Next Frontier of Targeted Therapy in Lymphoma

UChicago Medicine

K. Maddocks

R/R DLBCL: Are CAR-Ts Superior to Bispecific Antibodies?

Moffitt Cancer Center

A. Lazaryan

Polatuzumab Vedotin in 1L DLBCL: Perspectives on the POLARIX Trial

Juan Pablo Alderuccio

Considering Alternatives to CAR-T in R/R DLBCL

Julio Chavez

Hematologic Malignancies Update: Treatment Strategies for AML, DLBCL…

Total Health

M. Rotta

New Treatment Strategies in DLBCL

UChicago Medicine

L. Sehn

Safety Profile of Ruxolitinib in Patients With MF

Icahn School of Medicine at Mount Sinai

D. Tremblay

Tafasitamab/Lenalidomide for DLBCL: Which Patients and What to Expect

Amit Mehta

Therapeutic Advances in T-Cell Lymphoma in 2024

Penn Medicine's 2024 Updates in Care of the Hematologic Malignancies Patient

S. Barta

SOHO 2023: The New Algorithm for 2L LBCL

SOHO 2023 Eleventh Annual Meeting

J. Westin